Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models.
Mol Cancer Ther
; 10(9): 1542-52, 2011 Sep.
Article
em En
| MEDLINE
| ID: mdl-21764904
ABSTRACT
We describe here the identification and characterization of 2 novel inhibitors of the fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases. The compounds exhibit selective inhibition of FGFR over the closely related VEGFR2 receptor in cell lines and in vivo. The pharmacologic profile of these inhibitors was defined using a panel of human tumor cell lines characterized for specific mutations, amplifications, or translocations known to activate one of the four FGFR receptor isoforms. This pharmacology defines a profile for inhibitors that are likely to be of use in clinical settings in disease types where FGFR is shown to play an important role.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Receptores de Fatores de Crescimento de Fibroblastos
/
Inibidores de Proteínas Quinases
/
Fatores de Crescimento de Fibroblastos
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Mol Cancer Ther
Assunto da revista:
ANTINEOPLASICOS
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
Suíça